Firstly, in the absence of a standardized questionnaire providing precise definitions of terms describing individual adverse effects, symptoms are likely to be perceived differently by participants
Thompson wasnt involved in the study
When to Consider Testing Testing may be useful: Before starting a GLP-1 medicine After a meaningful treatment change When diabetes goals are not being met When persistent gastrointestinal symptoms develop When food or fluid intake has significantly decreased When kidney or liver risk is already present When a prior result was abnormal When a healthcare provider recommends follow-up Testing frequency should be based on individual risk rather than an automatic monthly or quarterly panel for everyone
Only 10% of those thinking of taking a treatment said the same thing
However, there are many drawbacks that commercials and marketing campaigns dont tell you
If your BMI is below 27, the realistic path forward involves focusing on the health conditions that could qualify you through the comorbidity pathway if your BMI is at least 27, or working with a provider who assesses your metabolic risk beyond the BMI number alone
&srotate=0)
